Data from FDA - Curated by EPG Health - Last updated 24 November 2019

Indication(s)

INDICATIONS AND USAGE For collection of blood and preparation of red blood cells, plasma and platelets. Platelets are not intended to be produced when using ‘doubles’ .

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Anticoagulation Therapy for Stroke Prevention

Anticoagulation Therapy for Stroke Prevention

Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.

Load more

Related Content

Advisory information

Special warnings and precautions
GENERALPRECAUTIONS Use Aseptic Technique. Use only if solution is clear. If preparing a platelet concentrate, the platelet-rich plasma should be separated from the red blood cells within 8 hours after blood collection. If preparing fresh frozen plasma, separate from the red blood cells and place in the freezer at -18 °C or colder within 8 hours after collection. Store CPDA-1 preserved red blood cells at 1—6 °C for up to 35 days and use as indicated. * During processing, always observe the following precautions: 1. Sealing should be done in a manner that avoids fluid splatter. 2. Always dispose of blood-contaminated products in a manner consistent with established BIOHAZARD safety procedures.
Adverse reactions
ADVERSE REACTIONS There are no known potential adverse reactions associated specifically with the CPDA-1 Blood Collection Set with Sampling System.

More information

Category Value
Authorisation number BN800077
Agency product number 593YOG76RN
Orphan designation No
Product NDC 53157-130
Date Last Revised 26-06-2019
Type HUMAN PRESCRIPTION DRUG
Marketing authorisation holder Haemonetics Manufacturing Inc